WARNING: This product is for research use only, not for human or veterinary use.
MedKoo CAT#: 401680
Description: PD98059 also known as PD-98059, is a potent and selective inhibitor of MAP kinase kinase (also known as MAPK/ERK kinase or MEK kinase). It mediates its inhibitory properties by binding to the ERK-specific MAP kinase MEK, therefore preventing phosphorylation of ERK1/2 (p44/p42 MAPK) by MEK1/2. MAPK ERK1/2 is involved in TLR-induced production of cytokines.
MedKoo Cat#: 401680
Chemical Formula: C16H13NO3
Exact Mass: 267.08954
Molecular Weight: 267.28
Elemental Analysis: C, 71.90; H, 4.90; N, 5.24; O, 17.96
Synonym: PD98059; PD-98059; PD 98059; PD098059
IUPAC/Chemical Name: 2-(2-amino-3-methoxyphenyl)-4H-chromen-4-one
InChi Key: QFWCYNPOPKQOKV-UHFFFAOYSA-N
InChi Code: InChI=1S/C16H13NO3/c1-19-14-8-4-6-11(16(14)17)15-9-12(18)10-5-2-3-7-13(10)20-15/h2-9H,17H2,1H3
SMILES Code: O=C1C=C(C2=CC=CC(OC)=C2N)OC3=C1C=CC=C3
Appearance: Solid powder
Purity: >98% (or refer to the Certificate of Analysis)
Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility: Soluble in DMSO, not in water
Shelf Life: >2 years if stored properly
Drug Formulation: This drug may be formulated in DMSO
Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code: 2934.99.9001
The following data is based on the product molecular weight 267.28 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
|Concentration / Solvent Volume / Mass||1 mg||5 mg||10 mg|
|1 mM||1.15 mL||5.76 mL||11.51 mL|
|5 mM||0.23 mL||1.15 mL||2.3 mL|
|10 mM||0.12 mL||0.58 mL||1.15 mL|
|50 mM||0.02 mL||0.12 mL||0.23 mL|
1: Huang CT, Huang DY, Hu CJ, Wu D, Lin WW. Energy adaptive response during parthanatos is enhanced by PD98059 and involves mitochondrial function but not autophagy induction. Biochim Biophys Acta. 2014 Mar;1843(3):531-43. PubMed PMID: 24321770.
2: Lee JM, Kim JD, Oh EJ, Oh SH, Lee JH, Im GI. PD98059-impregnated functional PLGA Scaffold for direct tissue engineering promotes chondrogenesis and prevents hypertrophy from mesenchymal stem cells. Tissue Eng Part A. 2014 Mar;20(5-6):982-91. doi: 10.1089/ten.TEA.2013.0290. Epub 2013 Dec 11. PubMed PMID: 24188591; PubMed Central PMCID: PMC3938927.
3: Pathania AS, Joshi A, Kumar S, Guru SK, Bhushan S, Sharma PR, Bhat WW, Saxena AK, Singh J, Shah BA, Andotra SS, Taneja SC, Malik FA, Kumar A. Reversal of boswellic acid analog BA145 induced caspase dependent apoptosis by PI3K inhibitor LY294002 and MEK inhibitor PD98059. Apoptosis. 2013 Dec;18(12):1561-73. doi: 10.1007/s10495-013-0889-4. PubMed PMID: 23948751.
4: Yao J, Qian C, Shu T, Zhang X, Zhao Z, Liang Y. Combination treatment of PD98059 and DAPT in gastric cancer through induction of apoptosis and downregulation of WNT/β-catenin. Cancer Biol Ther. 2013 Sep;14(9):833-9. doi: 10.4161/cbt.25332. Epub 2013 Jun 14. PubMed PMID: 23792588; PubMed Central PMCID: PMC3909552.
5: Han YH, Moon HJ, You BR, Yang YM, Kim SZ, Kim SH, Park WH. The MEK inhibitor PD98059 attenuates growth inhibition and death in gallic acid-treated Calu-6 lung cancer cells by preventing glutathione depletion. Mol Med Rep. 2010 May-Jun;3(3):519-25. doi: 10.3892/mmr_00000291. PubMed PMID: 21472273.
6: Cotrim CZ, Amado FL, Helguero LA. Estrogenic effect of the MEK1 inhibitor PD98059 on endogenous estrogen receptor alpha and beta. J Steroid Biochem Mol Biol. 2011 Mar;124(1-2):25-30. doi: 10.1016/j.jsbmb.2010.12.020. Epub 2011 Jan 12. PubMed PMID: 21236341.
7: Di Paola R, Crisafulli C, Mazzon E, Genovese T, Paterniti I, Bramanti P, Cuzzocrea S. Effect of PD98059, a selective MAPK3/MAPK1 inhibitor, on acute lung injury in mice. Int J Immunopathol Pharmacol. 2009 Oct-Dec;22(4):937-50. PubMed PMID: 20074457.
8: Di Paola R, Galuppo M, Mazzon E, Paterniti I, Bramanti P, Cuzzocrea S. PD98059, a specific MAP kinase inhibitor, attenuates multiple organ dysfunction syndrome/failure (MODS) induced by zymosan in mice. Pharmacol Res. 2010 Feb;61(2):175-87. doi: 10.1016/j.phrs.2009.09.008. Epub 2009 Oct 9. PubMed PMID: 19819333.
9: Al-Shanti N, Stewart CE. PD98059 enhances C2 myoblast differentiation through p38 MAPK activation: a novel role for PD98059. J Endocrinol. 2008 Jul;198(1):243-52. doi: 10.1677/JOE-08-0151. Epub 2008 May 8. PubMed PMID: 18467380.
10: Kanda S, Kanetake H, Miyata Y. Long-term exposure of human renal carcinoma cells to PD98059 induces epithelial-mesenchymal transition-like phenotype and enhanced motility. Mol Cell Biochem. 2008 Feb;309(1-2):69-76. Epub 2007 Nov 14. PubMed PMID: 18000741.